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ABSTRACT 
Objectives: (I)To evaluate the efficacy of Sulfadoxine/pyrimethamine as a prophylactic                        
intervention in prevention and control of malaria during pregnancy;(II) to compare effect 
on neonatal low birth weight (LBW) between  intervention and control groups; (III) to 
determine the proportion of maternal, neonatal and placental parasitaemia among 
intervention control groups. 
Material and methods: A prospective case/control interventional study of 113 
primigravidae, 57 as a intervention group and 56 as a control group selected through a 
cluster sampling technique. After taking their verbal consent, the intervention group 
received two doses of sulfadoxine/pyrimethamine (SP) in the second and early third 
trimesters, and followed up according to the WHO antenatal care schedule. 
The outcomes include the following: (I) Reduction of malaria episodes during pregnancy 
in primigravidae ; (II) reduction of prevalence of neonatal low birth weight; and (III) 
determination of the prevalence of maternal, neonatal and placental parasitaemia. 
Results: The frequency of malaria episodes during pregnancy in primigravidae was 
found to be 14.6% and 29.7% for intervention and control groups respectively and there 
was a significant statistical difference between the two groups (P< 0.00001). 
The proportion of LBW was found to be 3.5% and 35.8% for the intervention and 
control groups respectively and there was a significant statistical difference between the 
two groups (Z=6.99). 
The proportion of maternal, neonatal and placental parasitaemia was found to be (10.9% 
and 54.9%),(11.1% and 54.9%) and (24% and 50%) for intervention and control groups 
respectively and there was a significant difference between the two groups regarding 
maternal and neonatal parasitaemia, while there was no significant difference regarding 
placental parasitaemia. 
Conclusion: Sulfadoxine/pyrimethamine is an effective prophylactic intervention for 
reducing malaria episodes during pregnancy and improving neonatal birth weight. 
Keywords: Malaria, Pregnancy, Prophylaxis, Sulfadoxine/pyrimethamine(SP), Primigravidae, Newborn,  
Placenta. 
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Introduction. Malaria constitutes a major threat to health. It affects all age groups. 
The disease causes anaemia in children and pregnant women and increases the 
vulnerability to other diseases.1  
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Malaria is a major disease that causes 300 million to 500 million new infections and 
1.5 to 2.7 million deaths every year. 2,3,4. 
Plasmodium falciparum is the principal cause of severe disease, it may infect humans 
at any time from conception to adulthood. Malaria infection probably results in 3.5 
million low birth weight (LBW) infants every year, since an estimated 24 million 
pregnant women live in malaria endemic areas.5 
According to the WHO 585000 women die each year from pregnancy-related causes, 
99 % of whom are from developing countries. The maternal mortality rate is highest 
in West Africa (1,020 maternal deaths per100, 000 live-born) while it is 27/100,000 
in industrialized countries. Direct obstetric causes account for 80 % of deaths: 
hemorrhage, infection, dystonia, hypertension and abortion. Indirect causes are 
essentially anemia, malaria hepatitis B and AIDS.6 
It has long been realized that during first and second pregnancies clinically immune 
women are more susceptible as they develop high-density parasitaemia. 7.   
Pregnancy is associated with increased susceptibility to malaria. It is generally 
agreed that this increased risk ends with delivery. The incidence of episodes of 
malaria increases significantly during the second and third trimesters of pregnancy. 
The duration of fever during the episodes of malaria was longer and the prevalence 
and density of asymptomatic malarial parasitaemia were significantly higher during 
pregnancy and the early post-partum period than during the other periods.8 
Pregnant women attracted twice the number of Anopheles gambiae complex - the 
predominant African malaria-carrying mosquito - than their non-pregnant 
counterparts. It is postulated that physiological and behavioral changes that occur 
during pregnancy are responsible for increased attractiveness, which could be 
important in intervention strategies aimed at protecting this high-risk group against 
malaria.9 
Malaria is associated with reduced birth weight, which was thought to be affect the 
result of placental insufficiency, which leads to intrauterine growth retardation 
(IUGR). 10,11 
Malaria contributes to antenatal anaemia and slowing of fetal growth, especially in 
primigravidae. It is thought that these effects harm the mother and the baby, and 
intervention to prevent and mitigate the effects of malaria are often recommended. 
12 
 
 
Material and methods. A prospective case/control interventional study of 113 
primigravidae, 57 as a intervention group and 56 as a control group were selected 
through a cluster sampling technique. The study involved two localties east and west 
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of  Wad Medani city, the eastern locality was selected randomly and it has 7 clusters, 
each around a health center from these centers, using a cluster sampling technique, 
two centers were selected for the study because they are well equipped especially for 
antenatal care (ANC) and laboratory facilities - Gezirat elfeel and Dardeg health 
centers -  each has assigned one day for ANC weakly. (Period of the study1999 – 
2001). 
     The first week was selected randomly for recruitment of intervention group and 
the second week for the control group and so on. 
The two groups were matched regarding thes ociodemographic characteristics 
Primigravidae at the beginning of their second trimester, after confirmation of the 
pregnancy with Ultrasongrahy and obtaining their verbal consent, were recruited in 
the study and then full history and detailed clinical examination were done.  
  The intervention group received two doses of sulfadoxine/pyrimethamine (SP) 
each consist of 3 tablets (500 mg Sulfa-doxine + 25mg pyrimethamine / tablet) in 
the second and early third trimesters, and followed up according to the WHO 
antenatal care schedule.13 
The side effects to SP were minimal, only nausea and vomiting were reported. 
All studied women were screened monthly with blood film (BF) for malaria using 
giemsa stain, haemoglobin (Hb) in g/dl  using colorometric method, urine for sugar 
and albumin, BF for malaria (species) + parasite count (u/l) , Hb and placental BF at 
the day of delivery. The newborn was also screened for malaria and its weight was 
recorded in Kgs within 24 hours of delivery. 
All positive cases of malaria in the control group and their children or any medical 
problem had been managed on the spot. 
Data was analysed by SPSS and tested with T-test, Chi-square test and Z-test. 
 
Results & Discussion. In this study 117 primigravidae were selected, 59 as 
intervention group and 58 as control group, 2 out of each group did not complete the 
study (one developed skin rashes and was withdrawn from the study and the other 3 
delivered outside Wad-Medani city).  
 
The age ranged between 17- 41 years with a mean of 25.03 +/- 4.83 for intervention 
group and 16 – 35 years with a mean of 24.92 +/- 4.68 for control group and there 
was no significant statistical difference between the two groups, so the two groups 
were matched regarding age. 
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The prevalence of malaria at enrolment was 16/57 (28.1%) and 14/56  (25%) for 
intervention and control groups respectively (table 1) and there was no statistical 
difference between them (P > 0.05), and this reflected the similarity in exposure and 
susceptibility to malaria at the time of the first antenatal visit, 14 as clinical immunity 
is decreased during pregnancy due to immunosuppressive effects of human chorionic 
gonadotrophin HCG.15, 16 
 
 
 
Table 1: Number of attacks of malaria among intervention and control groups. 
 
Malaria state BF result Intervention Control Sig./test 
Maternal malaria 
percentage at enrollment. 
+ve 16(28.1%) 
*n=57 
14(25%) 
n=56 
P>0.05     NS 
Maternal malaria 
percentage post intervention 
at ANC visits. 
+ve 36(14.6%) 
**n=246 
69(29.7%)n
=232 
P<0.0001 
Sig. 
Maternal malaria 
percentage at delivery 
+ve 6(10.9%)  
*n=55 
28(54.9%) 
n=51 
P<0.000003
Sig 
Percentage of newborn with 
parasites in heel blood at 
delivery.  
+ve 6(11.1%) 
***n=54 
28(54.9%) 
n=51 
P<0.000004 
Placental malaria 
prevalence at delivery 
+ve 6(24%)   
****n=25 
10(50%)  
n=20 
P>0.05     NS 
*n = number of women. 
  **n = number of visits. 
 ***n = number of newborn. 
 ****n = number of placentas. 
  
The prevalence of malaria during pregnancy post intervention at antenatal care visits 
was 36/246 (14.6%) and 69/232 (29.7%) for intervention and control groups 
respectively and it is low in intervention group compared with the control group 
(table 1) following the administration of SP prophylaxis and there was a highly 
significant statistical difference between the two groups (P<0.0001) and this result 
was comparable with study conducted in rural Malawi,17 using the same protocol and 
the same drug.  
The prevalence of maternal malaria at delivery was found to be 6/55 (10.9%) and 
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28/51 (54.9%) for intervention and control groups respectively and there was strong 
significant statistical difference (P<0.000003). This result (intervention group) when 
compared with two similarly designed studies in Malawi18 and Kenya19 (assessed at 
32/52) was high as they show a prevalence of 3% and 5.3% among intervention 
groups respectively20and this may be due to emergence of some strains resistant to 
sp. 
The prevalence of neonatal peripheral parasitaemia was very low in intervention 
group 6/54 (11.1%) compared with the control group 28/51 (54.9%) and there was a 
significant statistical difference (P<0.000004), and it was very high in the control 
group compared with a study conducted in Nigeria which gave a prevalence of 
21.6%. 21 
The prevalence of placental malaria (+ve BF) was 6/25 (24%) and 10/20 (50%) in 
the intervention and control groups respectively (table 1) and there was an obvious 
difference although it was not significant (P>0.05). The placental malaria in 
intervention group was high when compared with studies conducted in Malawi18 and 
Kenya22 which shows an incidence of 9% and 12% respectively. 
 
Table2: Newborn weight distribution among intervention and control groups within 
24 hours after delivery. 
Newborn  weight (kg) Intervention Controls 
< 2.5 2  (3.5 %) 19  (35.8%) 
>  2.5 55 (96.5%) 34 (64.2%) 
Total 57 53 
      Mean               2.91 +/- 0.41                          2.44 +/- 0.29 
      Z= 6.99 Sig. ( This test is a variety of t-test) 
 
Table (2) shows the mean birth weight for intervention and control groups. The 
incidence of low birth weight (LBW) was high in the control group 19/53 (35.8%) 
than the intervention group 2/57 (3.5%) and it was statistically significant (Z=6.99), 
pointing to the value of SP as an effective prophylaxis against malaria during 
pregnancy in primigravidae as malaria is a known cause of LBW.23, 12,24 So SP 
prophylaxis reduced malaria frequencies and improved birth weight.25 The incidence 
of LBW in the control group was high when compared with study conducted in 
Sudan which showed an incidence of 18.1%.26 
The incidence of LBW in intervention group (3.5%) was very low when compared 
with a similar study carried out in Kenya which gave an incidence of 8% and this 
reflected the strong effect of SP in improving birth weight.22,27 
EDITORIAL  
Gezira Journal Of Health Sciences 2004 vol.1(1)  
 
Gezira Journal Of Health Sciences 2004 vol.1(1) 
 
Table 3:Progress of pregnancy and its outcome among intervention and control 
group. 
Outcome of pregnancy Intervention group 
Control groups 
Neonatal deaths. 1  ( 1.8%) 3   (5.4%) * 
Premature -       - 1  (1.8%) * 
Abortion -     - 3    (5.4%) * 
Stillbirth 1   (1.8%) 0  0 * 
Congenital malformations. 1     (1.8%) 0   0 * 
Total 57   (100%) 56  (100%) 
*P > 0.05 NS 
 
The neonatal death was 1/57 1.8% & 3/56 5.4%, abortion was zero & 3/56 5.4% and 
prematurity was zero & 1/56 1.8% and they were more in the control group than the 
intervention group although the difference was not statistically significant P>0.05.  
The stillbirth in the intervention group followed prolonged obstructed labour and a 
congenital malformation occurred in a newborn of an elder primigravida (42 years 
age). 
 
Note: 
 This study was partially supported by WHO/TDR.  
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